Limiting GERD Progression in Older Patients: Reducing Costs Through Optimal Management

Sponsored by North American Center for Continuing Medical Education, LLC

Target Audience

This activity is designed for managed markets pharmacists.

Learning Objectives

After completing this activity, participants should be able to:

Describe the clinical and cost concerns of GERD disease progression
Identify atypical GERD symptoms frequently present in older patients
Outline the safety and efficacy of available GERD pharmacotherapies
Implement patient-centered treatment algorithms that promote optimal pharmacotherapy and reduce the burden of GERD

Credit Eligibility

To be eligible for documentation of credit, participants must participate in the full educational activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: October 28, 2008

Expiration Date: October 28, 2009

Estimated time to complete: 1 hour

Lecture Components

The slide presentation with audio, post-test, and evaluation form are available as a click-through via the menu at the top of the page.

CPE Accreditation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UPN 276-000-08-021-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact John Savage, Director, Medical Education, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535, or by e-mail at jsavage@naccme.com. The Director of Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME, may be made for a second level of review.

Grant Support

This program is supported by an educational grant from Takeda Pharmaceuticals North America, Inc.

Faculty

John E. Pandolfino, MD, MSCI
Associate Professor of Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Independent Clinical Reviewer

Frank K. Friedenberg, MD, MS (Epi), Associate Professor, Gastroenterology Section, Temple University School of Medicine, Philadelphia, Pennsylvania.

Planning Committee

The planning committee comprises Drs. Pandolfino and Friedenberg; and Rosemary Hodgson, Randy Robbin, John Savage, and William Kormos, NACCME.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Pandolfino: Consultant—AstraZeneca Pharmaceuticals, Santarus, TAP Pharmaceuticals; Scientific Advisor—Crospan; Promotional Speakers’ Bureau—AstraZeneca Pharmaceuticals, Santarus

Dr. Friedenberg: Grant/Research Support—Viro Pharma, Inc.; Scientific Advisor—Viro Pharma, Inc.

Ms. Hodgson, Mr. Robbin, Mr. Savage, and Mr. Kormos have disclosed no relevant financial relationships with any commercial interest.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation.

The faculty has disclosed that the following off-label/unapproved uses of drugs or devices will be discussed: use of baclofen, and double-dosing of proton-pump inhibitors for the treatment of GERD will be discussed.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2008 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the North American Center for Continuing Medical Education.